EGFR and esophageal adenocarcinoma: LYWS-23 submitted by T. Tousseyn was a patient with EGFR mutated adenocarcinoma of the lung, who was treated with chemotherapy and an anti-EGFR agent and developed a T-cell lymphoma with TFH phenotype and only focal scattered EBV positive cells, and LYWS-173 from N. Demko was a patient with esophageal adenocarcinoma, who developed an EBV+ polymorphic LPD arising after chemotherapy.